Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Enterprise Value (2020 - 2025)

Maxcyte (MXCT) has disclosed Enterprise Value for 6 consecutive years, with -$105.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 31.27% to -$105.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$105.7 million, a 31.27% increase, with the full-year FY2024 number at -$154.5 million, up 8.2% from a year prior.
  • Enterprise Value was -$105.7 million for Q3 2025 at Maxcyte, up from -$126.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$73.4 million in Q2 2021 to a low of -$255.9 million in Q3 2021.
  • A 5-year average of -$184.7 million and a median of -$179.3 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 633.67% in 2021, then skyrocketed 31.27% in 2025.
  • Maxcyte's Enterprise Value stood at -$255.0 million in 2021, then rose by 10.86% to -$227.3 million in 2022, then increased by 25.98% to -$168.3 million in 2023, then grew by 8.2% to -$154.5 million in 2024, then soared by 31.56% to -$105.7 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Enterprise Value are -$105.7 million (Q3 2025), -$126.6 million (Q2 2025), and -$138.3 million (Q1 2025).